fbpx
Investments

GlaxoSmithKline (GSK) Development makes HUF 18 billion investment in Gödöllő factory

New investment will deliver vaccine components to aid billions of children everywhere

Foreign Minister Péter Szijjártó spoke at the opening of the new vaccine manufacturing plant, which created 104 high value-added jobs, stating that he was happy to see such a global giant choose Hungary, and Hungarian workers’ expertise, to expand. 

GSK, the world’s sixth largest pharmaceutical companies, has been operating in Hungary since 2001 and became a strategic partner of Hungary’s government in 2014. GSK’s factory in Gödöllő will now employ 300 people and manufacture diphtheria and tetanus components for a new area of application, giving the factory a strategic role in the company. The Hungarian government supported this expansion with HUF 1.8 billion.

This new development is the second part of a program initiated in 2016 and enables the company to produce all DT and TT (Diphtheria Toxoid and Tetanus Toxoid) products at one location, delivering greater efficiency and doubling the factory’s market share of vaccine sales. The components produced will help vaccinate billions of infants and children around the world.

Show More

Related Articles

Back to top button
Close